title: Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
abstract: BACKGROUND
  Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a proinflammatory enzyme bound to low-density lipoprotein cholesterol and other circulating lipoproteins. Two measures of Lp-PLA(2), mass and activity, are associated with increased cardiovascular risk. Data are sparse regarding genetic determinants of Lp-PLA(2) mass and activity, and no prior data are available addressing genetic determinants of statin-induced changes for this proinflammatory biomarker.
  
  
  RESULTS
  We performed a genome-wide association study of Lp-PLA(2) mass and activity at baseline and after 12 months of rosuvastatin therapy (20 mg/d) among 6851 participants of European ancestry from the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and performed replication in a meta-analysis of 13 664 participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Novel associations were identified and replicated at MS4A4E and TMEM49 for baseline Lp-PLA(2) activity with genome-wide significant joint P values (P=2.0 × 10(-11) and P=2.9 × 10(-9), respectively). In addition, genome-wide associations (P<5 × 10(-8)) were identified and replicated for baseline Lp-PLA(2) mass at CETP and for Lp-PLA(2) activity at the APOC1-APOE and PLA2G7 loci. Among 2673 statin-allocated participants, both Lp-PLA(2) mass and activity were reduced by >30% and low-density lipoprotein cholesterol by 50% after 12 months of statin therapy (P<0.001 for both). Variants in ABCG2 and LPA were associated with change in statin-induced Lp-PLA(2) activity at genome-wide significance but were substantially attenuated after adjustment for statin-induced changes in lipid levels.
  
  
  CONCLUSIONS
  Genome-wide significant associations at MS4A4E and TMEM49 may reflect novel influences on circulating levels of Lp-PLA(2) activity. In addition, genome-wide significant associations with rosuvastatin-induced change in Lp-PLA(2) activity were observed in ABCG2 and LPA, likely because of their impact on statin-induced low-density lipoprotein cholesterol lowering.
authors.affiliation: Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. aychu@partners.org
authors.forename: Audrey Y
authors.initials: AY
authors.lastname: Chu
authors.forename: Franco
authors.initials: F
authors.lastname: Guilianini
authors.forename: Harald
authors.initials: H
authors.lastname: Grallert
authors.forename: Josée
authors.initials: J
authors.lastname: Dupuis
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Barratt
authors.forename: Fredrik
authors.initials: F
authors.lastname: Nyberg
authors.forename: Daniel I
authors.initials: DI
authors.lastname: Chasman
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D015894:Genome, Human / Q000235:genetics; D055106:Genome-Wide Association Study; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008970:Molecular Weight; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D015203:Reproducibility of Results; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase